Photos: 

Some evaluation reports are public and can be downloaded from this website, while others are restricted to MSF users and can only be accessed via Tukul. This limitation is mainly due to the sensitive nature of the operational contexts and the resulting content. However, there are internal discussions about making all evaluation reports publicly searchable. If you are an MSF association member, reports are made available on various associate platforms such as www.insideOCB.com.

Chemical prevention of seasonal malaria (CPS) has been implemented in Niger since 2013, pursuant to the recommendations of the World Health Organization (WHO) and the national anti-malaria policy. It consists of a mass campaign involving the administration of curative doses of sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) to children between the ages of 3 and 59 months for three days, at 28-day intervals, between July and November.

Alena Koscalova
29/09/2015

The Ebola Workshop in Dakar, held over 3 days in June 2015, brought together experienced Ebola field people and HQ staff from diverse specialties and all MSF sections to reflect on lessons learned so far and make recommendations in the areas of outreach response, patient care, human resources and strategy. Participants placed a high value on intersectional approaches within MSF, and on strong engagement with key external organizations in preparing flexible, adapted, more effective responses to future outbreaks of Ebola or other mass epidemics. 

By Patricia Kahn, with input from Sebastian Stein. Based on summaries by Amanda Tiffany, Roberta Petrucci, Ruth Kauffman and Sebastian Stein.
01/07/2015

La chimio-prévention du paludisme saisonnier (CPS) a été mise en œuvre au Niger depuis 2013, conformément aux recommandations de l'Organisation mondiale de la Santé (OMS) et à la politique nationale de lutte contre le paludisme. Elle se déroule sous la forme d’une campagne de masse qui consiste en l’administration de doses curatives de sulphadoxine-pyriméthamine (SP) et d'amodiaquine (AQ) durant trois jours, à 28 jours d’intervalle entre juillet et novembre, aux enfants de 3 à 59 mois.

by Alena Koscalova
01/02/2015